Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Doctor Care Anywhere Group PLC operates a digital healthcare platform providing virtual GP consultations, mental health services, and physiotherapy primarily in the UK and Ireland. The company monetizes through B2B contracts with insurers, corporate clients, and NHS partnerships, competing in the rapidly expanding telehealth market against Babylon Health, Push Doctor, and traditional primary care. Recent 143% annual stock appreciation reflects investor optimism around post-pandemic digital health adoption, though the company remains pre-profitability with negative operating margins.
Doctor Care Anywhere generates revenue through per-member-per-month (PMPM) fees from insurers and employers, typically £2-5 per covered life, plus utilization-based fees for consultations (£25-40 per virtual GP visit). The platform aggregates demand to achieve network effects, with gross margins around 57% reflecting low variable costs once technology infrastructure is built. Pricing power depends on demonstrating cost savings versus traditional in-person care (estimated 30-40% lower per consultation) and improving access metrics. Competitive advantage lies in regulatory compliance with UK CQC standards, integration with existing health IT systems, and clinical quality outcomes that drive contract renewals.
New enterprise contract wins with major insurers or NHS trusts, particularly multi-year agreements with guaranteed minimum volumes
Monthly active user (MAU) growth rates and consultation volume trends indicating platform adoption and utilization
Path to profitability milestones including quarterly EBITDA improvements and operating leverage demonstration
Competitive dynamics in UK telehealth market including regulatory changes affecting virtual prescribing or reimbursement rates
M&A activity or consolidation in digital health sector affecting valuation multiples
Regulatory risk from changes to UK virtual prescribing rules, CQC oversight requirements, or NHS reimbursement policies that could restrict service offerings or compress margins
Technology disruption from AI-powered diagnostic tools or large tech entrants (Amazon Care, Apple Health) with superior distribution and capital resources
Reversion to in-person care preferences post-pandemic reducing telehealth utilization from 2020-2022 peaks
Market consolidation with well-capitalized competitors (Babylon Health pre-collapse raised $1B+, Push Doctor acquired by Medicspot) creating pricing pressure and customer acquisition cost inflation
NHS expanding in-house digital services (NHS App, 111 online) reducing demand for third-party platforms
Traditional primary care networks developing hybrid models that combine in-person relationships with virtual convenience
Negative equity position (ROE 857% with negative book value) indicates accumulated losses exceed shareholder capital, creating potential going concern risk if profitability timeline extends
Cash burn with near-zero operating cash flow requires ongoing capital raises, risking shareholder dilution at unfavorable valuations if market conditions deteriorate
Current ratio of 1.33 provides limited liquidity cushion if revenue growth disappoints or customer churn accelerates
moderate - B2B revenue from corporate wellness programs shows cyclical sensitivity as employers cut benefits during downturns, but NHS and insurer contracts provide countercyclical stability as cost containment pressures increase demand for lower-cost virtual care alternatives. Consumer discretionary spending affects direct-to-consumer segment. Overall, healthcare services demonstrate defensive characteristics with 0.7-0.8 GDP beta.
Rising rates negatively impact valuation multiples for pre-profitable growth companies as discount rates increase, compressing forward P/S multiples. Higher rates also increase cost of capital for cash-burning operations, potentially accelerating need for dilutive equity raises. However, business operations have minimal direct interest rate exposure given negligible debt levels (negative net debt position based on -95.02 D/E ratio suggests net cash).
Minimal direct credit exposure. Revenue primarily from investment-grade insurers, government entities, and large corporates with low default risk. No significant accounts receivable financing or customer credit risk. Company's own access to capital markets could tighten during credit stress, but current cash position and low capex requirements provide buffer.
growth - Attracts speculative growth investors betting on digital health secular trends and potential multi-bagger returns if company achieves profitability and market leadership. Recent 143% annual return and 34.6% quarterly gain indicate momentum-driven trading. Not suitable for value or income investors given negative earnings, no dividends, and uncertain path to sustainable profitability. Micro-cap status ($0.1B market cap) limits institutional ownership.
high - Micro-cap pre-profitable growth stock with limited liquidity exhibits elevated volatility. Stock price highly sensitive to quarterly user growth surprises, contract announcements, and broader risk appetite for unprofitable tech/healthcare names. Recent 143% annual return followed by continued momentum suggests beta >2.0 relative to broader market.
